Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Simes

Showing results (41-50 of 265) with videos related to

Pageof 27
Sort By:
BMJ Open|February 25, 2014
Which lipid measurement should we monitor? An analysis of the LIPID studyPaul P Glasziou, Les Irwig, Adrienne C Kirby, et al.
Health and Quality of Life Outcomes|January 14, 2018
When do patient reported quality of life indicators become prognostic in breast cancer?Chee Khoon Lee, Malcolm Hudson, John Simes, et al.
BMJ Open|February 14, 2024
Development of clinically meaningful quality indicators for contemporary lung cancer care, and piloting and evaluation in a retrospective cohort; experiences of the Embedding Research (and Evidence) in Cancer Healthcare (EnRICH) ProgramBea Brown, Kirsty Galpin, John Simes, et al.
The Cochrane Database of Systematic Reviews|June 11, 2015
Taxane-containing regimens for metastatic breast cancerDavina Ghersi, Melina L Willson, Matthew Ming Ki Chan, et al.
Journal of Clinical Epidemiology|May 24, 2019
Prevalence of trial registration varies by study characteristics and risk of biasAidan Christopher Tan, Ivy Jiang, Lisa Askie, et al.
Australian and New Zealand Journal of Public Health|January 16, 2004
Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) studyDianna Magliano, Danny Liew, Helen Pater, et al.
BMC Medical Research Methodology|April 2, 2010
Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|August 5, 2011
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapySumitra Ananda, Anna K Nowak, Lawrence Cher, et al.
Medical Care|December 25, 2008
Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetesPhilip M Clarke, Alison J Hayes, Paul G Glasziou, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Next-generation sequencing, should I use anti-HER2 therapy for <i>HER2</i>-amplified tumors off-label? Illustrating an extrapolation frameworkDoah Cho, Sarah J Lord, John Simes, et al.
Pageof 27

Showing results (41-50 of 265) with videos related to

Sort By:
Pageof 27
BMJ Open|February 25, 2014
Which lipid measurement should we monitor? An analysis of the LIPID studyPaul P Glasziou, Les Irwig, Adrienne C Kirby, et al.
Health and Quality of Life Outcomes|January 14, 2018
When do patient reported quality of life indicators become prognostic in breast cancer?Chee Khoon Lee, Malcolm Hudson, John Simes, et al.
BMJ Open|February 14, 2024
Development of clinically meaningful quality indicators for contemporary lung cancer care, and piloting and evaluation in a retrospective cohort; experiences of the Embedding Research (and Evidence) in Cancer Healthcare (EnRICH) ProgramBea Brown, Kirsty Galpin, John Simes, et al.
The Cochrane Database of Systematic Reviews|June 11, 2015
Taxane-containing regimens for metastatic breast cancerDavina Ghersi, Melina L Willson, Matthew Ming Ki Chan, et al.
Journal of Clinical Epidemiology|May 24, 2019
Prevalence of trial registration varies by study characteristics and risk of biasAidan Christopher Tan, Ivy Jiang, Lisa Askie, et al.
Australian and New Zealand Journal of Public Health|January 16, 2004
Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) studyDianna Magliano, Danny Liew, Helen Pater, et al.
BMC Medical Research Methodology|April 2, 2010
Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|August 5, 2011
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapySumitra Ananda, Anna K Nowak, Lawrence Cher, et al.
Medical Care|December 25, 2008
Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetesPhilip M Clarke, Alison J Hayes, Paul G Glasziou, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Next-generation sequencing, should I use anti-HER2 therapy for <i>HER2</i>-amplified tumors off-label? Illustrating an extrapolation frameworkDoah Cho, Sarah J Lord, John Simes, et al.
Pageof 27